

Efficacy Claims against the 2009 (H1N1)  
Pandemic Influenza A Virus  
for Hard Surface Disinfectant Drug Products

The current H1N1 pandemic is giving rise to questions related to the requirements for efficacy claims against Influenza A H1N1 virus for hard surface disinfectant drug products. The Therapeutic Products Directorate (TPD) has reviewed the requirements for data in support of H1N1 claims and we are very pleased to announce that Health Canada has now posted a notice to sponsors entitled “Requirements for Efficacy Claims against the 2009 (H1N1) Pandemic Influenza A Virus for Hard Surface Disinfectant Drug Products” at

[http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/disinfect-desinfect/notice\\_avis\\_disinfectant\\_h1n1\\_ld-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/disinfect-desinfect/notice_avis_disinfectant_h1n1_ld-eng.php).

This Notice applies to hard surface disinfectant drug products regulated under Part C, Division 1 of the *Regulations* that have received a Drug Identification Number (DIN) pursuant to Section C.01.014.2. and establishes the process and requirements to enable companies to make direct and indirect claims of product efficacy against H1N1. It does not apply to changes to disinfectant products that have received a Notice of Compliance (NOC) in accordance with Division 8 of the *Regulations*.